What is Andrew Hillman's professional background?

Andrew Hillman is the Principal of Hillman Ventures, a Dallas family office he founded in January 1995. He has a 30 plus years operating record, with 10 companies founded, co-founded, or operated, and 4 exits.

How does Hillman Ventures allocate its capital?

Hillman Ventures allocates its capital across various investments, including FDA-regulated biotech companies, such as Bone Solutions Inc, which exited in 2021 with an FDA 510(k) orthopedic device.

What philanthropic efforts is Andrew Hillman involved in?

Andrew Hillman is involved in philanthropic efforts at the Lamplighter School in Dallas, where he donated the Andrew Hillman Family Room, and at SMU, where he established the Andrew Hillman Scholarship for Entrepreneurs (founded 2024) and the Andrew Hillman Grant for Biotech.

What is Andrew Hillman's expert witness practice?

Andrew Hillman has a senior paralegal role at a private law firm, and has been involved in various legal cases, including the organization and funding of Levine et al v Google consumer privacy action.

Where is Hillman Ventures based?

Hillman Ventures is based in Dallas, Texas, and has a presence in six international partner jurisdictions, including Mexico, Australia, Israel, Turkey, UAE, and Colombia.

What is Andrew Hillman's publication record?

Andrew Hillman writes The Hillman Letter on Substack, and has an ORCID identifier of 0009-0001-5396-321X.

Is Andrew Hillman involved in any notable legal cases?

Andrew Hillman is not a defendant in the Forest Park Medical Center criminal case, and has been involved in various other legal cases, including the organization and funding of Levine et al v Google consumer privacy action.

Dallas, Texas • Hillman Ventures, est. 1995

Leadership. Strategy. Growth.

Principal of Hillman Ventures. Three decades in FDA-regulated healthcare. Frontier biotech, regulatory strategy, and Dallas philanthropy.

Request a Conversation

30+

Years in FDA-regulated healthcare

Family office

Capital, since 1995

Frontier

Exosome, regenerative, oncology

Dallas

Seat of practice and philanthropy

Practice

What I do, today.

01. Investing

Hillman Ventures.

Private family office investing in frontier biotech. Three priorities. Inflammation. Damaged tissue. Tumor-based cancers. Capital allocated with operator judgment behind it.

hillmanv.com

02. Writing

The Hillman Letter.

Essays on FDA regulatory strategy, biotech investment thesis, and capital allocation discipline at family offices. Ships from Dallas. Short, direct, sourced.

Read latest

03. Advising

Strategic Counsel.

Pathway review, standing retainer, board director or observer, and investor diligence support for FDA-regulated biotech operators and family office allocators.

andrewhillmanadvisor.com

04. Expert Witness

Healthcare Compliance.

Expert witness in federal and state civil matters where the regulatory record is the central question. Limited engagements per year. Inquiry by invitation.

andrewjhillman.com

Approach

Thirty years of FDA-regulated work, compressed into one operating philosophy.

"Manufacturing decisions follow product lock. Headcount follows revenue or paid clinical milestones. Regulatory strategy precedes site selection. These are not slogans. They are filters."

Hillman Ventures was founded in Dallas in 1995. The original mandate was simple. Invest in FDA-regulated healthcare ventures where the science is real, the regulatory pathway is defensible, and the operators can absorb agency guidance at the cadence the science requires. Three decades on, that mandate has not changed.

The portfolio today concentrates on frontier biotech. Inflammation and damaged-tissue regeneration. Targeted oncology mechanisms that reach tumors small molecules and immunotherapies do not. Exosome biologics on the 351(a) pathway. Cell and gene therapy programs where the manufacturing process is the product.

The work outside the portfolio is the work that shaped the inside. The Hillman Letter on FDA regulatory strategy. The Andrew Hillman Scholarship for Entrepreneurs and the Andrew Hillman Grant for Biotech at Southern Methodist University. The Andrew Hillman Family Room at the Lamplighter School.

— ⋄ —

In biologics, the process is the product. Locking process before product is the most common capital destruction event I see in this category.

Andrew Jonathan Hillman · Principal, Hillman Ventures

Properties

The full operating footprint.

Hillman Ventures

Family office. FDA-regulated frontier biotech since 1995.

hillmanv.com

Hillman Advising

Strategic advisory. Regulatory pathway. Board director and observer.

andrewhillmanadvisor.com

Andrew J. Hillman

Expert witness practice in healthcare compliance.

andrewjhillman.com

The Hillman Letter

Essays on FDA regulatory strategy and capital discipline.

thehillmanletter.substack.com

FixCancer.org

Targeted Osmotic Lysis. Patient navigation for advanced solid tumor cancers.

fixcancer.org

The Public Record

Primary sources. Maintained for full transparency.

andrewhillmanrecord.com

A complete public record. Primary sources.

Maintained as a matter of practice. Anyone deciding whether to take a call, sit on a board, or invest alongside Hillman Ventures may read the primary record directly.

Visit the public record

Built across three decades.

Laboratory skills

Co-Founder and Investor experience at Infinity Toxicology LLC.

Hospitals

Three experiences at Champion Medical Center Baton Rouge plus two other companies.

Executive coaching

Operator-grade coaching for founders and clinical executives.

Leadership development

Programmatic leadership work inside FDA-regulated organizations.

Public speaking

Conference, panel, and continuing-legal-education speaking engagements.

Three decades, in plain English.

If you do not work in healthcare regulation, this is the short version. Each row is a different kind of company built or backed across three decades.

1995 - 2000

Pharmacy and lab roots

Started Hillman Ventures family office. Built first retail and compound pharmacy. Founded clinical laboratory operations.

2000 - 2008

Pharmacy and lab expansion plus first hospital roles

Cornell, Silver Creek, Meyerland, Treetop, Apothecary Shop, COR Pharma. Toxicology labs Medicus, Infinity, United, Safe-Tox, Reliant. First surgical hospital partnerships.

2007 - 2013

Surgical hospital era

Bone Solutions early funding. Hospital Business Concepts consulting. Victory Healthcare network forms: Houston, Plano, Craig Ranch, Landmark, Beaumont, East Houston, Mid Cities, Fort Worth.

2014 - 2016

Strategic exits

Victory Houston and Plano sold to Nobilis Health (NASDAQ HLTH). Craig Ranch sold to Methodist Health System. Landmark sold to Cumberland Surgical of San Antonio.

2018 - 2022

Federal matter and reset

Forest Park federal matter resolved with one plea, five other cases dismissed, dropped, or declined. Sentence served. Supervised release terminated early. Full primary-source record at andrewhillmanrecord.com.

2022 - today

Frontier biotech rebuild

Bone Solutions divested 2021. Mesenchymal exosome biologics program structured for FDA 351(a) BLA pathway. Targeted Osmotic Lysis program advances internationally with partner clinics. Hillman Advisor consulting practice formalized. The Hillman Letter publishes on Substack.

Texas and Louisiana, mostly.

Most companies and facilities operated within a tight geography. Pins below mark the locations referenced in the public record.

Texas anchor. Louisiana research collaboration through LSU Health Sciences Center.